Sensitivity of Vi phages III to γ-radiation in the presence of cisplatin

• Authors: Tomasz Dabrowski , Bartlomiej Kwiatkowski
• Languages of publication: EN

Abstracts

EN

In this study we determined Vi bacteriophage III sensitivity to native cisplatin, γ radiation (60Co) or to irradiated cisplatin, and checked the possibility of enhanced Vi bacteriophage III inactivation under combined exposure to cisplatin and γ radiation. We used highly purified phage suspensions in 0.9% NaCl solution or phosphate-buffered saline. Phage suspensions were titrated using a double agar layer method. Our study implies that survival of Vi bacteriophage III shows an exponential inverse correlation with cisplatin concentration in the incubation medium and the time of phage incubation in the presence of cisplatin. The use of irradiated cisplatin reduces phage survival in comparison with suspensions containing non-irradiated cisplatin. Irradiation of phage suspension with cisplatin causes a significant increase of phage inactivation in comparison with either treatment alone. Our results suggest that presence of cisplatin in irradiated medium enhances the radiobiological effect on Vi bacteriophages III.

Keywords

EN

cytotoxicity; Vi bacteriophage III; cisplatin; irradiation

• Journal: Acta Biochimica Polonica
• Year: 2005
• Volume: 52
• Issue: 2
• Pages: 545-550

Dates

published

2005

received

2004-10-09

revised

2004-12-21

accepted

2005-01-24

(unknown)

2005-05-31

Contributors

author

Tomasz Dabrowski

• Department of Physics and Biophysics, Medical University of Gdańsk, Gdańsk, Poland

author

Bartlomiej Kwiatkowski

• Department of Physics and Biophysics, Medical University of Gdańsk, Gdańsk, Poland

References

• Adams M (1959) Bacteriophages. Interscience Publ Inc., New York.
• Bray GA (1960) Anal Biochem 1: 279.
• Broszkiewicz R (1971) Chemical Methods of Ionizing Radiation Dose Determination. Wydawnictwo Naukowo-Techniczne, Warszawa (in Polish).
• Coughlin CT, Richmond RC (1989) Semin Oncol 16 (Suppl 6): 31-43.
• Dabrowski T (1999) Wspolcz Onkol 3: 249-252.
• Dewit L (1987) Int J Radiat Oncol Biol Phys 13: 403-426.
• Douple EB, Richmond RC (1978) Br J Cancer 37 (Suppl 3): 98-102.
• Drobnik J, Blahuskova A, Vasilukova S, Krekulova A (1975) Chem Biol Interact 11: 365-375.
• Eastman A (1990) Cancer Cells 2: 275-280.
• Filipski J, Kohn KW, Bonner WM (1980) Chem Biol Interact 32: 321-330.
• Kratz F, Schütte MT (1998) Cancer J 11: 60-67.
• Kwiatkowski B, Beilharz H, Stirm S (1975) J Gen Virol 29: 267-280.
• Kwiatkowski B, Dabrowski T, Pienkowska D (1998) Ann Acad Med Gedan 28: 139-144.
• Laurencot CM, Kennedy KA (1995) Oncol Res 7: 371-379.
• Lippert B, ed (1999) Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. Verlag Helvetica Chimica Acta, Zurich.
• O‘Dwyer PJ, Johnson SW, Hamilton TC (1997) In Cancer. Principles and Practice of Oncology. DeVita VT Jr, Hellman S, Rosenberg SA, eds, pp 418-432. Lippincott-Raven, Philadelphia, New York.
• Richmond RC, Powers EL (1976) Radiat Res 78: 251-257.
• Richmond RC, Zimbrick JD, Hykes DL (1977) Radiat Res 71: 447-460.
• Shooter KV, Howse R, Merrifield RK, Robins AB (1972) Chem Biol Interact 5: 289-307.
• Tanaka N, Saito H, Kimoto H, Taketo A (1998) J Biochem 123: 821-826.
• Tucholski J, Dabrowski T, Zaremba E, Gazda D, Kwiatkowski B (1999) Ann Acad Med Gedan 29: 17-23.
• Villani G, Le Gac NT, Hoffmann JS (1999) In Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. Lippert B, ed, pp 135-157. Verlag Helvetica Chimica Acta, Zurich.
• Wang K, Lu JF, Li R (1996) Coordination Chem Rev 151: 53-88.
• Yachnin JR, Wallin I, Lewensohn R, Sirzen F, Ehrsson H (1998) Cancer Lett 132: 175-180.
• Zaremba E (1990) Sensitivity of Vi bacteriophages III to irradiation (in Polish). Doctoral dissertation, Medical University of Gdansk, Gdansk.
• Zaremba E, Kwiatkowski B, Ciesielski B (1989) Nukleonika 34: 37-50.